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Syndrome
Although intervention strategies have been proven to
reduce the incidence andmortality of tumors in individuals
with Lynch syndrome, it is not straightforward to distin-
guish families with this cancer syndrome from those with
much more common forms of colon and other cancers.
Moreira et al. recently completed a large pooled analysis
to compare various strategies for the identification of these
patients from cohorts with colorectal cancer. Their results
emphasize the lack of sensitivity of certain previously sug-
gested approaches, including the Amsterdam criteria, to
the identification of families with Lynch syndrome.
Although a universal screening strategy for all individuals
diagnosed with colorectal cancer is the most sensitive for
the detection of Lynch syndrome, not too far behind
is a combined strategy in which screening is initiated
either when the patient with colorectal cancer is diagnosed
at%70years of age orwhen thepatientmeets at least oneof
the revised Bethesda criteria for Lynch syndrome. This
second, more selective strategy has the added benefit of
reducing the false-positive rate for the screen.
Moreira et al.(2012). JAMA 308, 1555–1565.Setting Standards for Next-Generation
Sequencing in the Clinical Setting
From process to validation to interpretation, there are
inherent challenges of scale when exomes and genomes
are sequenced. We all need clean results for our research,
but in the clinical testing arena, the bar needs to be set
evenhigher before results are returned to patients. InNature
Biotechnology’s November issue, which focused on DNA
sequencing, there is a summary of the principles and guide-
lines developed by the Next-Generation Sequencing: Stan-
dardization of Clinical Testing workgroup convened by the
United States Centers for Disease Control and Prevention.
This group developed recommendations for validation,
quality control, proficiency testing, and referencematerials
for the use of next-generation-sequencing protocols in
clinical testing. The group also adapted performance char-
acteristics of the Clinical Laboratory Improvement Amend-
ments for next-generation-sequencing applications.
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The AmericanApparent Homozygosity in Genetic Testing
When is a homozygote not really a homozygote? This is
a question addressed by a recent report by Landsverk
et al. in Genetics in Medicine. This group from Baylor
explored a set of close to 300 cases for whom they found
apparent homozygosity for a recessive mutation in any
of 40 different genes. The most straightforward explana-
tion is that these were actually homozygous mutations
inherited in aMendelian fashion, but proving this assump-
tion has implications for the patient and family in terms of
recurrence risk and confidence in the diagnosis. Although
parental testing for teasing this out was recommended for
all cases, it was completed in just over one-quarter of the
samples. Of these, the mutation was not present in both
parents in 12% of cases. Alternative explanations for this
apparent homozygosity included allele dropout, unipa-
rental disomy, and deletions overlapping the point muta-
tion. Not all cases could be resolved, and nonpaternity
was likely to be an explanation in at least some of them.
The authors used their experience to propose an algorithm
for the confirmation of apparently homozygous mutations
in probands.
Landsverk et al. (2012). Genet. Med. 14, 877–882.There Isn’t Room Here for the Both of Us
Why do we get all of our mitochondria from our
mothers? Our mtDNA is not necessarily all the same—
in other words, there can be heteroplasmy for mtDNA
haplotypes—so it would seem as though biparental inher-
itance could provide a source of evolutionarily advanta-
geous genetic diversity. Instead, it appears that hetero-
plasmy, even for wild-type mtDNA, can be detrimental,
and this might explain the uniparental inheritance of
this organelle. A group led by Doug Wallace generated
mice that were on a congenic nuclear background but
were heteroplasmic for two wild-type mtDNAs. When
they stopped selectively breeding the mice to maintain
this heteroplasmy, they saw that one mtDNA haplotype
was favored over the other such that there was rapid
loss of this haplotype over the course of one to two
generations. Although mice homoplasmic for either
mtDNA haplotype were equally fertile and otherwise
indistinguishable, heteroplasmy led to cognitive andta, GA 30322, USA
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behavioral changes in the mice; compared to mice homo-
plasmic for either haplotype, the heteroplasmic mice
were less active and slower to learn and exhibited
changes in anxiety and fear responses. Fluctuations in
the level of heteroplasmy between mothers and their
children or between different tissues within the same
person have been recognized for some time. This has
typically been viewed as a random process in which het-
eroplasmy is influenced by genetic drift more than
anything else. These new data suggest that heteroplasmy
itself is genetically unstable and leads to adverse physio-
logical effects. This could explain why we stick with the
maternal mtDNA rather than mixing the paternal and
maternal mtDNA at each generation.
Sharpley et al. (2012). Cell 151, 333–343.
Exome Schmexome
Clinical exome sequencing is a revolution in genetic
testing, but let’s not forget that the exome includes only976 The American Journal of Human Genetics 91, 975–976, Decemba small fraction of the whole genome or that the remainder
might have some interesting bits in it as well. One of these
bits was recently uncovered by Yin et al., and it might
explain the pathogenesis of Prader-Willi syndrome. This
group identified a new class of long noncoding RNAs
with a small nucleolar RNA at each end (sno-lncRNAs).
These RNAs are widely expressed, particularly in pluripo-
tent cells, and some of the most abundant are encoded
within chromosomal region 15q11-q13, which is deleted
in many cases of Prader-Willi syndrome. The sno-lncRNAs
accumulate at a single nuclear location that appears to
correspond to the site at which they are generated. Those
encoded in the 15q11-q13 region bind to the alternative
splice regulator Fox2 and regulate its function at very
specific sites within the nucleus, and the affected splice
targets include genes involved in neural function. Thus,
in the absence of these particular noncoding RNAs, higher
effective levels of Foxp2 might alter splicing patterns and,
as a result, neural development.
Yin et al. (2012). Mol. Cell 48, 219–230.This Month in Our Sister JournalsModeling Skin Cancer Risk
Although we are all at risk of developing skin cancer and
should wear sunscreen to reduce this risk, some of us are
more genetically susceptible than others. Beyond looking
at family history and the paleness of one’s skin, predicting
those at increased risk is tricky because skin cancer is
a complex trait. Although there has been some success
in identifying genetic variation associated with the risk
of skin cancer, each variant appears to have a small effect,
and there are likely to be many other positions in the
genome that influence this risk. Vazquez et al. considered
various approaches to the incorporation of genetic infor-
mation into models predicting skin cancer risk and evalu-ated them by using SNP and clinical data from the first
two generations of the Framingham Heart Study. Rather
than pinpointing the exact alleles that have been associ-
ated with skin cancer risk, they used either data from
ancestry informative markers or various amounts of
whole-genome SNP data. Incorporation of genetic infor-
mation in any form improved their predictive capacity,
but the use of genome-wide SNP information yielded the
most accurate predictions. Beyond predicting skin cancer,
this type of approach could be relevant to many other
complex traits.
Vazquez et al. (2012). Genetics. Published online October 10,
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